GHK-Cu is a copper-binding peptide found in human plasma. Discovered in 1973, it is a protective and regenerative substance commonly found in skin and hair products. It has demonstrated effects in tissue repair as well as effects that are anti-inflammatory, anti-cancer, anti-anxiety, and anti-pain (1).
Much of GHK’s effects are likely due to its action in binding copper ions and its role in copper metabolism. However, recent advancements in genetic research indicate that GHK-Cu also regulates many human genes and thus is involved in gene expression. As many as 31.2% of human genes are affected by GHK with a change of greater than 50%. As such, GHK-CU is able to exert effects on skin regeneration, blood vessel and nerve growth, anti-cancer mechanisms, and more (1).
GHK-Cu has several beneficial effects supported by research, including:
When it comes to cosmetic applications of GHK-Cu, there is some evidence that GHK-Cu could be of benefit in the form of topical creams and serums. Thus, individuals may opt to include this ingredient into their skin routine. However, larger scale clinical trials that assess GHK-Cu’s utility systemically and in other medical indications are needed to fully categorize it’s clinical benefit.
GHK-Cu is not approved by the US Food and Drug Administration (FDA) as a drug. However, when used in cosmetic formulations, it is categorized as a cosmetic and thus falls under a different regulatory category.
GHK-Cu is not currently eligible for 503A/503B compounding but is currently a category 2 bulk substance nominated under 503A or 503B. It has some safety concerns associated with its use (2).
Compounded injectable drugs that contain GHK-Cu are thought to carry an immunogenicity risk. This is due to the possibility of aggregation and peptide-related impurities. Additionally, data in humans is limited and thus the safety profile not well-categorized (2).
The use of GHK-Cu is accessible via the topical route for cosmetic purposes, which is supported by some preliminary clinical evidence. However, further research is required for other indications, and it is not currently approved by the FDA as a drug.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
Understanding how peptides influence the body is key to achieving meaningful results. Our peptide therapy services are built to help patients optimize outcomes while maintaining a strong emphasis on clinical safety.
References
